Pathos AI closed a $237.0M Series E follow-on round — its fifth institutional round — at an approximately $3 billion post-money valuation led by Bristol Myers Squibb (NYSE: BMY) alongside existing investors. The New York-announced clinical-stage AI and technology company said the raise reflects operational momentum from its proprietary Foundry AI platform advancing its own therapeutic pipeline of drugs. The available excerpt did not disclose specific metrics such as revenue, clients, or employee count, nor a detailed use of proceeds or expansion plans beyond pipeline advancement.